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1BACKGROUND
1. EPIDEMIOLOGY OF HIV INFECTION
1.1  Global HIV estimates
HIV remains a global health problem of unprecedented dimensions. Despite 
prevention efforts, the HIV/AIDS pandemic continues to expand globally at the
rate of 13,000 new infections/day, showing no sign of slowing, particularly in 
low- and middle-income countries, where about 95% of infected persons live. 
According to the World Health Organization (WHO) and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), a total of 33.4 million [31.1-35.8 million]
people, including 2.1 million children [1.2-2.9 million] were estimated to be 
living with HIV/AIDS through the end of 2008, with a prevalence threefold 
higher than 1990 (Table I) [1].
As regards new infections, they reached more than 2.7 million [2.4-3.0 million]
in 2008 with 430,000 [240,000-610,000] children less than 15 years. HIV-related 
deaths were 2 million.
Table I: HIV/AIDS global estimates in 2008.
People living with HIV/AIDS
Adults      Male 15.6 million
Female                                       15.7 million
Children < 15 years                                      2.1 million
Total                                                           33.4 million
New HIV infection in 2008
Adults      2.3 million
Children < 15 years                                         430,000
Total                                                             2.7 million    
Deaths from AIDS in 2008
Adults      1.7 million
Children < 15 years                                         280,000
Total                                                             2.0 million
2Unknown 27 years ago, HIV has already caused an estimated 25 million death 
worldwide. HIV is among the leading causes of death worldwide and it causes 
more deaths than any other infectious disease. Around 95% of HIV infected 
people live in non-industrialised countries with not sufficient financial resources  
to deal with the HIV/AIDS epidemic. It is estimated that the vast majority of 
AIDS deaths are due to inadequate access to HIV prevention and treatment [2].
Heterosexual transmission is now the dominant mode of transmission and 
accounts for more than two-third of all HIV infections worldwide, although
transmission in IDU (injecting drug users) and MSM (men who have sex with 
men) constitute a significant fraction of infections (10% and 5-10%, respectively)
[1,3]. Mother-to-child transmission of HIV  continues to occur at significant rates 
in the developing world, accounting for roughly 400,000 new infections annually 
[2,4,5].
Transmission through injection drug use appears to play a major role of HIV 
epidemics in several region of the world, particularly Eastern Europe and Asia [6].
In developed countries, the interplay between increased high risk sexual behaviour 
and injecting drug use fuels HIV epidemics.
The global epidemic is not homogenous within regions (Fig.1).
Sub-Saharan Africa remains the region most heavily affected by HIV infection:
home to just over 10% of the world population, it accounts for more than two 
thirds (22.7 million) of the global number of infected people and for 72%
(1.4 million) of all AIDS deaths [1,2]. Moreover, 90% of all children affected 
worldwide live in that region. Within the region, South-Africa is the worst 
3affected country, with more than 5.7 million people living with HIV. The leading 
mode of HIV transmission in Sub-Saharan Africa is through heterosexual route.
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Fig.1 Global adult HIV/AIDS prevalence by region in 2008 (million people).
Asia is becoming the epicentre of second largest epidemic with 350,000 new
infections annually and an estimated 4.7 million people living with HIV at the end 
of 2008 [1].
In Central Asia and in countries of the former Soviet Union, the HIV epidemic 
has increased faster between 2000 and 2006 (20-fold increase) than in any other 
area of the world, reaching an estimated 1.5 million HIV cases at the end of 2008. 
Nearly 90% of the HIV cases were reported from the Russian Federation and from 
Ukraine (infection rate: over 200/million) [7,8]. The vast majority of them were 
found among people below the age of 30 years (by comparison, in Western 
Europe some 30% of people with HIV fall in that age group). HIV epidemic in the 
region is driven by injecting drug use and increasingly by heterosexual 
transmission.
4An estimated 2.3 million people are living with HIV in North America and in 
Western and Central Europe. In high-income countries, where the great majority 
of people who need antiretroviral treatment have access to it, people living with 
HIV are surviving longer than infected people elsewhere [1].
In the United States, throughout the 1980s, the number of new AIDS cases 
increased rapidly. With the advent of HAART in 1995, there was a step decline in 
the number of new AIDS cases and deaths. Since 2000, however the decline in the 
number of persons who progress to AIDS each year has levelled off. 
Currently, an estimated 1.1 million individuals in the United States are living with 
HIV infection, one-fifth of whom are unaware of their infection and thus, miss the 
opportunity to receive life-saving antiretroviral therapy [9,10].
Despite the substantial reductions in deaths and AIDS diagnoses since the mid-
1990s, the US epidemic continues, with an estimated 50,000 new HIV infections 
occurring each year, many of which occur in MSM and ethnic minority 
populations [11].
The largest proportion of newly diagnosed HIV cases was among homosexual 
males (almost half cases),  followed by infections due to high-risk heterosexual 
contact (about 30%), to injection drug use (22%) and due to a combination of 
homosexual transmission and injection drug use (5%) [11-13].
In Latin America, an estimated 170,000 new HIV infections occurred in the 2008, 
bringing the number of people living with HIV to an estimated 2 million [1,2]. 
HIV trends in Latin America have also been relatively stable in the past decade, 
with most transmission attributed to MSM and heterosexual intercourses.
5MSM account for the majority of new HIV infections in Australia and New 
Zealand [1].
1.2  European Union HIV estimates
According to UNAIDS estimates, the adult HIV prevalence in the European 
Community (EC) was 0.3% in 2007. It was generally lower in Northern countries 
such as Sweden and Finland (0.1%) than in Southern countries such as Portugal 
(0.5%), Spain (0.5%) and Italy (0.4%). Around 850,000 people were estimated to 
be living with HIV in the European Union at the end of 2008 [1,7].
HIV epidemic continues to occur at substantial rates in EC with evidence of an
increase of new  diagnoses from 2000 to 2008 (42 to 61 cases per million). About 
26,000 newly diagnosed cases of HIV infection were reported by the countries of 
the EU in 2008, with the highest rates being reported from Estonia (400/million), 
Latvia (158/million) and United Kingdom (119/million) [14].
Rates of HIV diagnosed cases have doubled also in Bulgaria, Czech Republic, 
Hungary, the Netherlands, Slovakia and Slovenia; rates have increased by more 
than 50% in Germany, Norway, Lithuania and United Kingdom.
After falling dramatically in the late 1990s, following the introduction and 
widespread use of combination antiretroviral treatment, AIDS incidence in the EU 
countries has decline steadily. Thus, the number of reported AIDS cases has 
decreased  by more than 50% between 2000 and 2008 [7].
EU countries with the highest rates of AIDS diagnosis are Estonia (46/million), 
Latvia (44/million), Portugal (36/million) and Spain (29/million).
6In EU countries the proportion of heterosexually acquired cases of infection 
exceeds 50% of the total, whereas over a third of new HIV cases have been 
reported among MSM (reaching 50% of cases in Czech Republic, Hungary,
Slovakia and Slovenia) and about 10% of cases are seen among IDU (the largest 
transmission group being in Poland, Estonia and Lithuania) [7,15,16]. 
1.3  HIV estimates in Italy
In Italy, to obtain reliable data on the HIV epidemic, local surveillance systems of 
the new HIV diagnoses have been set up since 1988 in some regions and 
provinces (Piemonte, Liguria, Friuli Venezia-Giulia, Veneto, Puglia, Emilia-
Romagna, Lazio, Trento, Bolzano, Sassari, Catania). After a rapid spread of HIV 
infection in the 1980s, there has been a progressive decrease in the number of new 
diagnoses during 1990s; in more recent years this trend has levelled-off [17-20]. 
In 2008, an estimated 4,000 people (6.7 per 100,000 inhabitants) became newly 
infected with HIV in Italy, bringing to 170,000-180,000 the number of individuals 
living with HIV. About 60% of newly diagnosed patients have AIDS [21].
The mean age of the newly infected people is 34 ys in women and 38 ys in men. 
The incidence is raising among immigrants, where one third of the total number of 
new infections occurs [22].
AIDS incidence in Italy is estimated to be of 20 cases/million. Since the AIDS 
mortality peaked in 1995 reaching 4,500 deaths per year, there has been a 
progressive decline in mortality rate (147 deaths in 2008 vs. 588 deaths in 2004)
due to effective HAART (Highly Active Antiretroviral Therapy) [7].
7The epidemiology of HIV infection has greatly changed over time since 1988, 
when injecting drug users were driving the epidemic. Among adults diagnosed 
with AIDS in Italy, in the last decade there has been an increase in heterosexual 
(from 25% in 1998 to 44% in 2008) and homosexual (from 17% to 24%) 
transmission route, where as the transmission through the injection drug users has 
decreased by half (from 48% to 22%) [21,23].
1.4  HIV estimates among MSM
As in the beginning of the epidemics, consistently high levels of HIV infection 
have been found among MSM worldwide, with more than 200,000 people
becoming newly infected each year [1,24,25].
MSM include a variety of subsets, ranging from homosexual to bisexual, 
transgender and self-identified heterosexual men who engage in sex with other 
men. They represent a high risk population, contributing significantly to the 
spreading of HIV infection [26].
In much of the high income countries, HIV transmission among MSM is the main 
driver of the epidemics.
In the United States, MSM represent the risk group most severely  affected by 
HIV, accounting for nearly half HIV cases (500,000 people infected with HIV 
infection). Additionally, this is the only risk group in the U.S in which the annual 
number of new HIV infections is steadily increasing since the early 1990s, with an 
estimated 29,000 newly-diagnosed HIV infections [27].
In their most recent account, the European surveillance network, EuroHIV,
reported that MSM constituted 40% (about 8,300 cases; 60 per million men aged 
815-64 years) of all newly diagnosed HIV infections in EU countries in 2008. In 
EU countries, the number of HIV cases identified among MSM increased by 40% 
between 2003-2008, thus suggesting a resurging epidemic involving this high risk 
population [7,28]. The highest rate was reported in United Kingdom (130/million
male population), where HIV cases rose by 74% between 2000 and 2007, and the 
lowest in Romania (1/million men) [29]. In the Netherlands, Hungary, Czech 
Republic, Slovakia and Slovenia, the total number of new reported HIV cases in 
MSM represented more than 50% of all new reported cases [26].
In former Soviet Union countries, less than 1% of new HIV infections were in 
MSM (about 120 cases) in 2008 [7,26]. HIV prevalence rates among MSM were
estimated to be 5% in Georgia, 6% in Russian Federation and have reached as 
high as 10-23% in Ukraine [1,25,26].  
Lack of awareness of HIV infection status is a likely reason for continuing high-
risk behaviours in MSM. The using of alcohol and illegal drugs (substance abuse), 
appears to contribute to increased risk for HIV infection and other STDs (sexually 
transmitted diseases). 
Current guidelines recommend that screening be performed at least annually in 
high risk groups, such as MSM [30,31].
92. STRUCTURE AND BIOLOGY OF HIV VIRUSES
2.1 Structure and genomic organization of HIV-1/2
The human immunodeficiency viruses (HIV-1 and HIV-2) are members of the 
Lentivirus genus of the Retroviridae family, commonly called retroviruses
[32-34].
The HIV genome contains the gag, pol, and env genes which encode structural 
proteins, viral enzymes, and envelope glycoproteins, respectively (Table II).
The gag gene encodes a precursor protein (p55) that is cleaved into four major 
structural proteins: p17, p24, p9 and p6. 
Products of the pol gene include three enzymes: protease (p11), reverse 
transcriptase (p66 and p51) and integrase (p32). The protease is responsible for 
cleavage of gag-pol precursor polypeptides into functionally active proteins. The 
reverse transcriptase of HIV-1 is a RNA-dependent DNA polymerase responsible 
for replicating the RNA genome. The integrase is required for provirus integration 
into the host genome. 
The env gene encodes a glycosylated polypeptide precursor gp160 that is cleaved 
to form the envelope surface glycoprotein (gp120) and the transmembrane 
glycoprotein (gp41).
In addition, HIV genome contains at least six short regulatory sequences involved 
in the activation of HIV transcription and in the modulation of  viral gene 
expression (tat, rev, nef, vif, vpr, vpu) [35]. They encode auxiliary or regulatory 
proteins, including Trans-acting transcriptional activator- tat-, the Regulator of 
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viral expression-rev-, Negative effector -nef-, Viral infectivity factor -vif-, Viral 
protein U -vpu- and Viral protein R -vrp-.
The tat protein up-regulates HIV expression at transcriptional and post-
transcriptional level. The rev protein promotes nuclear export of unspliced or 
partially spliced viral mRNAs encoding the viral structural proteins. The vif gene 
encodes a protein that suppresses the antiretroviral effect of the cellular enzyme 
APOBEC, preventing viral DNA degradation. The vpu gene encodes a protein 
that promotes the CD4 degradation and influences virion release. The vpr gene 
encodes a protein that is involved in nuclear translocation of viral genome and  
facilitates virus production by arresting infected cells in G2 of the cell cycle. The 
nef gene encodes a protein that promotes down-regulation of cell-surface-bound 
CD4 (receptors) and cell surface expression of MHC I.
Nef is one of the first HIV proteins to be produced in infected cells and is the 
most immunogenic of the accessory proteins.
These genes are flanked by long terminal repeat (LTR) elements, that direct and 
regulate the expression of the viral genome.
HIV is an icosahedral virus 100 to 120 nm in diameter, provided with two 
identical copies of viral genomic RNA condensed in a nucleocapsid core.
The nucleocapsid core is cone-shaped and consists of two identical copies of 
single-stranded RNA approximately 9.2kb in length, strictly linked to the 
nucleocapsid protein –p9– (NC) and surrounded by the structural capsid proteins 
–p24–. 
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The viral envelope is derived from the outer limiting membrane of the host cell as 
the virus buds from infected cells. Inserted in the envelope are the envelope 
glycoprotein spikes, each consisting of a complex of three Env gp120-gp41 
heterodimers formed by the two major envelope proteins, the external gp120 and 
the transmembrane gp41. Underlying the envelope is the viral matrix protein p17. 
Biologically, HIV-2 is structurally analogous to HIV-1: the HIV-2 genome 
exhibits about 40% to 50% homology in overall nucleotide sequence. Some of its 
protein components differ, most notably the envelope glycoproteins gp105 and 
gp36, as well as the core protein p16 and p26 or the pol protein p68 and p34. 
The genome of HIV-2 lacks the vpu gene and exhibits the presence of vpx gene, 
which is a homolog of HIV-1 vpr [36] (Table II).
Table II: Major HIV-1/2 gene products.
Gene HIV-1 HIV-2 Protein/Function
P24 P26 Capsid protein
P17 P16 Matrix  protein
P9 P9 RNA binding protein
Gag
P6 P6 RNA binding protein
P66/p51 P68 Reverse transcriptase (RT)
P11 P14 Protease / post-translational processing of viral proteins 
Pol
P32 P34 Endonuclease and ligase / viral DNA integration into cell host genome
Gp120 Gp105 Envelope surface glycoproteinEnv
Gp41 Gp36 Envelope transmembrane protein
Tat P14 P14 Regulatory protein / transcription of viral genes
Rev P9 P9 Regulatory protein / viral mRNA transport out of the cell nucleus
Nef P27 P27 Accessory protein / decrease in level of CD4 receptor on cell surface
Vif P23 P23 Accessory protein / increase in virus infectivity
Vpr P15 P15 [Vpx] Accessory protein / promotion of virus replication
Vpu P16 - Accessory protein / release of new virions
The main antigenic differences between HIV-1 and HIV-2 are in the envelope 
glycoproteins which are responsible for much of the reactivity with antibodies. By 
contrast, antibodies to the gag and the pol proteins generally cross-react.
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Modes of transmission of HIV-2 are the same as for HIV-1 but it is less 
transmissible both sexually and perinatally. The frequency of transmission is 
reduced, probably due to a lower viral burden during the relatively long 
asymptomatic period of the disease [36]. 
2.2 HIV genotypes
The HIV epidemic appears to be the result of zoonotic virus transmission from 
non-human primates to human in Africa [37,38].
Two genetically distinct viral types of HIV have been identified: HIV type 1 
(HIV-1), discovered in 1983 and responsible for the worldwide AIDS pandemic, 
and HIV type 2 (HIV-2), first isolated in 1986 and endemic primarily in areas of 
West Africa (e.g. Guinea-Bissau and the Ivory Coast) and India. HIV-2, endemic 
in West African nations, has reached its highest prevalence of 8-10% in parts of 
Guinea-Bissau [32,39].
Sporadic outbreaks of HIV-2 infection have been reported outside Africa in
European countries with historical links with west Africa such as France, the 
United Kingdom and Portugal, and also in South America [36,40-42]. 
The two distinct types of human immunodeficiency viruses (HIV-1 and HIV-2) 
have closely related counterpart in African primates: the chimpanzee subspecies
Pan troglodytes troglodytes in West-central Africa have been identified as the 
natural reservoir of the HIV-1 pandemic and the sooty mangabeys in Western 
Africa as the source of HIV-2.   
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Due to this variability, phylogenetic sequence analyses of HIV-1 strains have 
identified three distinct groups: group M (major), which is responsible for most of 
the infections in the world; group O (outlier), a relatively rare viral form found 
originally in Cameroon and Gabon; group N, identified in only a limited number 
of people from Cameroon [43,44]. 
Group M, which is responsible for the vast majority (more than 95%) of HIV-1 
infections worldwide, comprises 9 subtypes, or clades (A-D; F-H; J and K), as
well as a growing number of major and minor circulating recombinant forms (at 
least 43), ranging from highly prevalent forms, such as CRF01_AE virus to a 
large number of CFRs that are relatively rare [45-47].
Subtype A viruses finds their highest concentration in areas of Central Asia, 
Eastern Africa and in Eastern European countries formerly constituting the Soviet 
Union. Subtype B dominates epidemics in Western and Central Europe, in the 
United States and Australia and is also common in several countries of Southeast 
Asia, Northern Africa, and the Middle East  and among South African and 
Russian homosexual men. 
Subtype C viruses is the overwhelming strain in Southern Africa, China and India. 
Certain HIV-1 isolates appear to be recombinant, containing sequences from more 
than one subtype. Many countries have co-circulating viral subtypes that are 
giving rise to new CFRs.
The relevance of circulating recombinant form (CRFs) in the global HIV-1 
pandemic is increasingly recognized, accounting for 18% of infections, and 
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representing the predominant local form in Southeast Asia (CRF01_AE) and in 
West and West Central Africa (CRF02_AG).
It is interesting to note that most new HIV-1 infections occur in developing 
countries, such as in Sub-Saharan Africa where non-B subtypes are prevalent, and 
then spreaded to industrialized countries through population movements from 
endemic countries [48]. 
HIV-2 variants are classified into eight major phylogenetic groups designed A 
through G, of which A and B are the majority strains.
These HIV-1 and HIV-2 groups and HIV-1 subtypes are now distributed 
throughout the world; all are found in Africa. HIV-1 clade C is becoming the most 
prevalent transmitted virus [43]. 
2.3 Replication cycle of HIV
The replication of HIV begins with the sequential  high-affinity binding of the 
gp120 protein to the target cell associated-CD4 molecule, followed by binding to 
a chemokine co-receptor (either CCR5 or CXCR4), which culminates in a gp41-
mediated fusion event and release of the viral core into the cell [49].
The CD4 molecule is a surface protein that marks the T-helper subset of T 
lymphocytes and is also expressed on  the surface of monocytes/macrophages and 
dendritic/Langerhans cells. 
Viruses able to utilize CCR5 can infect both macrophages and CD4+ T cells, while 
viruses that only utilizes CXCR4 usually infect only CD4+ T cells. 
RNA H activity and DNA polimerase generate a double-stranded DNA copy of 
the viral RNA able to migrate to the nucleus and integrate within the host cell
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genome, leading to the formation of the provirus [50]. Noteworthy, reverse 
transcriptase is an error-prone enzyme that generates multiple mutations at every 
cycle, thereby allowing the development of drug resistance and escape from 
immune surveillance.
At this point of the replication, the viral genome is vulnerable to cellular factors 
belonging to the APOBEC family, that can block the progression of infection this 
proteins bind to nascent reverse transcripts and deaminate viral cytidine, causing 
hypermutation of HIV genomes. HIV has evolved a powerful strategy to protect 
itself from APOBEC, through protein vif-mediated proteosomal degradation of 
APOBEC. In its DNA form, viral genome is inserted into the host genome.
Integrated DNA is transcribed into RNA by the host RNA polymerase II. Newly 
synthesized RNA can be multiply spliced to generate small transcripts that encode 
tat, rev or nef, in alternative can be singly spliced to express env, gag and pol, or 
remain unspliced and used as mRNA for gag, pol and env. Singly spliced and 
unspliced RNAs can be exported into the cytoplasm thanks to rev accessory 
protein. 
Transcribed viral mRNA is translated into viral proteins, that allow the 
assembling of the new virions at the cell surface, along with newly synthesized 
viral RNA. Mature virions are released ready to infect new cells and begin the 
replication cycle once again. The entire process  is extremely active, with 108-10 
viral particles produced each day. The proviral form may remain transcriptionally 
inactive or it may manifest varying levels of gene expression, up to active 
production of virus.  Activation of HIV expression from the latent state causes the 
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transcription of the integrated proviral RNA into genomic mRNA and its 
translation into proteins.
3. CLINICAL AND IMMUNOLOGICAL CORRELATES OF HIV INFECTION
3.1 Time-Course of HIV infection
The natural history of HIV infection can be divided into three phases: primary 
infection with a transient acute retroviral syndrome -ARS-, followed by a period 
of clinical latency and finally, symptomatic disease culminating in AIDS [51].
Primary infection, which covers the period from the onset of infection until 
seroconversion, is characterized by rapidly increasing high levels of HIV 
replication together with significant reduction of  HIV-specific CD4+ T 
lymphocytes. 
It is estimated that 50-70% of individuals with primary HIV infection experience 
an acute retroviral syndrome within 3-6 weeks after the onset of infection.
The clinical symptoms of acute HIV infection include flu-like or infectious 
mononucleosis-like symptoms, such as fever, pharyngitis, lymphadenopathy and 
maculo-papular skin rash, typically lasting 5-10 days. Severe illness, particularly 
acute encephalopathy, is occasionally found and is associated with poor 
prognosis.
Symptoms in the acute HIV syndrome occur along with a burst of plasma viremia, 
reaching levels up to 100 million copies of HIV-1 RNA per ml of plasma and 
gradually subside as an immune response to HIV, namely seroconversion,
develops, as a result of the emergence of host antiviral immune response.  
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Both cell-mediated (production of HIV-specific cytotoxic lymphocytes T) and 
humoral (production of complement fixing and neutralizing HIV-specific 
antibodies) immune responses are responsible for the significant decrease of 
plasma viral load. Although the immune response succeeds in down regulating the 
viremia, HIV replication is never completely abrogated and reach a steady state,
known as set-point, that is an important predictor of disease progression. High set-
points are prognostic of the risk for faster course until the development of AIDS 
and death, while lower set-points are associated with a slower disease progression. 
Detection of acute HIV infection, where the virus infectiousness has been shown 
to be enhanced approximately 26-foulds than the later stages of the disease, is 
important for patients and for public health [52].
The clinical latency with no therapy may last up to 10 year or longer and occurs
in the majority of patients. A small group of rapid progressors experiences AIDS 
within 1 to 2 years, whereas 5% to 10% of HIV long-term progressors remain 
symptom-free for longer than 20 years.
Active HIV replication is ongoing and progressive immunological impairment 
occur throughout the asymptomatic period. Widespread dissemination of the 
virus, with seeding of lymphoid organs and other tissue reservoirs results in 
depletion of CD4+ cells in gut-associated lymphoreticular tissue and in lymph 
nodes, thereby leading to a long-lasting quantitative loss of CD4+ helper T-cell 
function [53].
The continuous replication of HIV together with the elimination of host cells and 
chronic immune activation results over the years in loss in immune function and 
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increased susceptibility to infections and malignancies. The spectrum of clinical 
manifestations observed during the course of HIV infection changes as the CD4+ 
T-cell count declines.
The most common clinical findings are represented by constitutional symptoms 
(fever, weight loss and diarrhoea lasting more than 1 month), persistent 
generalized lymphadenopathy (enlargement greater than 1 cm in diameter of two 
or more extrainguinal nodes of at least three months’duration), recurrent 
infections by Herpes Zoster virus in more than one dermatome, oropharyngeal 
candidiasis (thrush), recurrent vulvovaginal candidiasis, oral hairy leukoplakia by 
Epstein Barr virus [54,55].
A diagnosis of AIDS is made in anyone with HIV infection and a CD4+ T-cell 
count less than 200 cells/L, and in anyone with HIV infection who develops one 
of the HIV-associated diseases considered to be indicative of a severe defect in 
cell-mediated immunity [54,56].
Conditions listed in the 1993 AIDS surveillance case definition include [56]:
- CD4+ T-cell count less than 200 cells/L;
- opportunistic infections caused by viruses (retinitis, pneumonia, enteritis or 
encephalitis by Cytomegalovirus; chronic ulcers, pneumonia or esophagitis
by Herpes simplex), bacteria (recurrent pneumonia by H.influentiae or S. 
pneumoniae), pulmonary and extra-pulmonary infections by M. tuberculosis, 
infections by M. avium complex -MAC- , recurrent Salmonella septicaemia), 
fungi (Pneumocystis jiroveci pneumonia, pulmonary and oesophageal 
candidiasis, disseminated cryptococcosis, coccidioidomycosis and 
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histoplasmosis) and protozoa (cerebral toxoplasmosis, chronic intestinal 
crysporidiosis and isosporiasis)
- neoplastic disease (Kaposi’s sarcoma, lymphomas, invasive cervical cancer).
- HIV encephalopathy;
- progressive multifocal leukoencephalopathy;
- wasting syndrome (debilitating weight loss and diarrhoea). 
Any of these conditions complicate the clinical course of the end stage of HIV 
infection and may cause death. 
Clinical studies show  that the HIV-2 disease progresses slower than in HIV-1 
infection,  resulting in a survival rate higher than that in the equivalent stage of 
HIV-1 infection with a mortality rate estimated to be two-thirds lower than that 
for HIV-1. However progression of disease in the later stages, as the immune 
response collapses, is fairly comparable between HIV-1 and HIV-2 [39,57-63]
(Table III).
Table III: Clinical and immunological features of HIV-1/2 infection.
HIV-1 HIV-2
Epidemiology
World distribution Pandemic West Africa (prevalence: 1-2%)
Infection time-course
Clinical evolution Majority develop AIDS<2% : long-term non progressors
~20-25% develop AIDS
remainder: long-term non progressors
Progression rate Fast: 5-10ys in the majority Slow: 10 ys or longer in the majority
Virus infectivity
Viral load in blood High Low
Virus replication rate Fast Slow
CD4 receptor affinity High (gp120) Low (gp105)
Immunology
Immune activation Variable Low
T-cell apoptosis Increased Lower than HIV-1
Decline in CD4+count Faster Slow or none in asymptomatic
CTL responses CTL escape mutants are common Strong in asymptomatic
Neutralizing antibody Less efficient, narrow specificity Efficient, broad specificity
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3.2  HIV virological and serological markers
Following exposure to HIV infection, HIV-specific markers appears in the blood 
in the following chronological order: HIV RNA, p24 antigen and anti-HIV 
antibodies [64]. 
Within the few first days of HIV infection, the virus starts an active replication in 
mucosal and lymphoid tissue that drains the inoculation site. This phase is 
referred to as the “eclipse phase” and usually lasts 10-14 days and occasionally up 
to 6 months. 
Viral active replication leads to the appearance of infectious viremia, as measured 
by plasma viral RNA, within two weeks after infection [65].
Viral antigens become detectable in plasma soon after viral RNA. The protein 
most widely used in HIV diagnosis is the capsidic protein p24, which appears 
usually within the first two to three weeks after acute infection. Its presence in the 
serum is transient, and its disappearance coincides with the development of both 
humoral and cellular responses to infection. 
The time period before antibody appears is referred to as serological “window” 
period and is characterized by seronegativity, detectable viremia (as measured by 
RNA or p24 antigen), and variable CD4 lymphocyte levels.
A transient immunoglobulin M (IgM) antibody response against the capsidic 
(p24) or envelope  (gp160, gp120, gp41) proteins is usually the first to appear and 
is followed by a long-lasting immunoglobulin G (IgG) response. The appearance 
of IgG antibodies against the core (p24) and envelope (gp160,120, 41) proteins 
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are then followed by antibodies against HIV viral enzymes, a process called 
“seroconversion”.
In most of infected persons, anti-HIV antibodies become detectable within three 
weeks, but in a small percentage of individuals (5%), seroconversion may require 
up to 6 months [65,66].
The appearance of antibody is clearly a major mechanism in decreasing viremia, 
as noted by the decrease in viral copies and p24 antigenemia, as antibody levels 
rise. 
With disease progression resulting in a decline in immunocompetence, virus 
replication increases (HIV RNA and p24 antigen levels increase), anti-p24 levels 
decrease, CD4+ cell count falls less than 200/L and the syndrome of AIDS 
manifests [67]. 
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4. STATE OF ART IN HIV TESTING
4.1 Overview of HIV diagnostic tests
The ability to diagnose HIV infection is a critical component in the efforts to 
decrease the ongoing spread of the epidemic, because HIV-serostatus awareness 
can help reducing risk behaviour associated with HIV transmission and provides
life-saving therapy to the newly diagnosed patients [68]. 
Diagnostic assays for HIV infection have evolved substantially since the 
introduction of antibody testing in 1985 [66,69].
HIV infection is identified either by the detection of HIV-specific antibodies in 
serum or plasma or by demonstrating the presence of the virus (nucleic acid 
detection) [70].
Current routine laboratory diagnosis of HIV infection is mainly based on the 
detection of specific anti-HIV antibodies. The HIV testing algorithm comprises 
initial serological screening for anti-HIV antibodies by using conventional 
enzyme immunoassays (EIA) or rapid immunoassays, followed by confirmatory 
testing of reactive specimens with a supplemental test (Western Blot or indirect 
Immunofluorescence assay -IFA- or Line Immunoassay -LIA-).
Regardless of the type of screening method used, a specimen producing a positive 
result will be tested again with the same or a different screening  test. If that 
sample is repeatedly reactive and independent sample of the patient test will be 
assayed with a confirmatory test. Screening  assays are highly sensitive, but not 
optimal with regard to specificity, particularly in testing low risk populations; 
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therefore the sequential use of confirmatory tests, that have a high specificity, 
enhances the accuracy of HIV diagnostic testing [71-74].
4.1.1 Screening tests for HIV detection
The enzyme immunoassay (EIA) is the most commonly used type of test to screen 
for HIV infection because of its simple methodology, high sensitivity, and 
suitability for high-volume testing. EIAs use an HIV antigen coated on a 
microwell plate to detect any HIV antibodies present in the specimen [64,75].
Four generations of EIAs have been developed, with later formats having 
improved test performance and shorter antibody-negative window period [76,77].
The first generation assays, developed in 1985 for diagnosis of HIV infections, 
used viral protein lysates derived from whole disrupted virus, adsorbed to the 
solid phase for detection of HIV specific antibodies. They had relatively high 
sensitivity but poorer specificity than was required for efficient screening
program. 
The second generation assays used HIV recombinant antigens (HIV capsidic and 
envelope proteins) as the target antigen bound to the solid phase and also 
incorporated a recombinant antigen for HIV-2. These assays had a high sensitivity 
and improved specificity with respect to the first-generation EIAs. 
First-and second-generation tests have a window period of about 6 to 12 weeks
for most individuals (Fig.2).
Third generation assays relies on a sandwich technology, where IgG or IgM 
antibodies from the specimen bind both to recombinant peptides adsorbed on the 
solid phase and to enzyme-conjugated recombinant antigens. The ability of these 
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assays to detect IgM, in addition to IgG, results in a estimated reduction of the 
antibody-negative window period to 20-30 days. In addition, third generation tests 
have the capacity to detect certain HIV subtypes, particularly HIV-1 Group O 
which were not included to previous generation tests [66].
Fourth generation assays combine IgM and IgG antibody and viral capsidic p24 
antigen detection, further reducing the timing of identification of HIV infection to 
two weeks and making detection of acute HIV infection feasible. 
Fig. 2: Time-line of HIV infection.
They are extremely good screening test with a sensitivity of >99.5% and provide 
for the simultaneous detection of antibodies to both HIV-1 and HIV-2. 
False positive reactions by using EIA testing may result from non-specific cross-
reacting antibodies in patients with autoimmune diseases, hepatic disease, 
pregnancy, undergoing multiple transfusions or recent immunization, particularly 
for the first generation assays.
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Rapid serologic HIV tests are defined as tests that are easy to perform, do not 
require instrumentation, provide results in less than 30 minutes and can be read 
visually, proving to be as accurate as the conventional EIAs [78,79].
Evaluations of these tests throughout the 1990s up to the present indicate 
generally good performance regardless of the format: currently available rapid 
HIV tests have demonstrated sensitivities and specificities comparable to those of 
standard HIV testing (more than 99%). Rapid tests are important tools for 
surveillance, screening, and diagnosis, and can be reliably done on plasma, serum, 
whole blood, or saliva [80].
As with EIA, the higher the prevalence of HIV within a population, the higher the 
positive predictive value of the rapid test. However, the positive predictive value 
of  a combination of HIV rapid tests is nearly 100% in regions of low HIV 
prevalence. Thus, when used in combination, rapid tests can increase both the 
speed at which results are reported, while minimizing the number of false 
positive. Moreover, the negative predictive value of a single rapid test in regions 
of low HIV prevalence is high. 
Rapid  HIV tests have proven particularly useful in certain situations, when results 
are needed with fast turnaround to allow prompt provision of antiretroviral 
treatment to prevent HIV transmission, including labour and delivery settings with 
women of unknown HIV  serostatus and employee exposures [81,82].
Rapid testing offers the convenience of point-of-care testing, providing patients 
with test results and immediate counselling during the initial visit. These rapid 
HIV tests are increasingly being used in various clinical scenarios to decrease the 
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number of missed opportunities for detection of HIV-infection. Their use is 
particularly applicable in specific clinical and non-clinical settings; public health 
settings; labour and delivery wards; in the management of occupational 
exposures; and in resource-constrained settings.
The two limitations of these serological tests are detection of infection during 
primary infection when antibodies are absent, and in infant younger than 18 
months who might bear maternal HIV-1 antibodies.  
The most extensively used formats suitable for rapid HIV testing are: 
immunoconcentration, immunochromatography and particle agglutination. 
Immunoconcentration assays are flow-through devices, based on simplified 
second-generation EIAs technology. They use HIV-1/2 specific peptides 
immobilized onto a solid phase with an underlying absorbent material containing 
a coloured marker. Diluted specimens are placed onto the membrane surface 
where HIV antibodies are captured and can be visually detected, as a coloured 
spot or line. These tests are provided with device controls to indicate the proper 
performance of the test steps and reagents. 
Immunochromatography tests are lateral-flow devices, that are usually based on 
third-generation technology [83]. They consist of a test strip that has HIV antigen 
immobilized onto a membrane surface, with an underlying absorbent pad 
impregnated with coloured reagents that permit the visual detection of anti-HIV 
antibodies. Specimens are placed in the tip of the strip and allowed to diffuse 
along the test region where HIV-specific antibodies will be captured and 
identified by the coloured reagent. 
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Particle agglutination assays rely on several different particle types (such as 
gelatine or latex) that are coated with HIV antigens. When mixed with a serum or 
plasma specimen, HIV antigen-coated beads are cross-linked into visible 
aggregates in the presence of HIV antibodies.
All these assays contain antigens for the detection of antibodies to HIV-1/2 and 
several of them assays permit the differentiation of HIV-1/2 infections by 
separating the two antigens on the strip.
4.1.2  Confirmation  testing  for  HIV
The Western Blotting (WB) procedure is the most extensively used confirmation 
assay. It is a highly specific immunoblot that allows for the detection of antibodies 
to specific capsidic and envelope HIV proteins. It relies on an electrophoretic 
technique to separate HIV antigens derived from lymphocyte-cultured viral 
lysates onto nitrocellulose sheets by molecular weight. 
HIV antibody-positive strips produce a characteristic pattern of bands related to 
antibodies direct against specific HIV proteins [80].
A positive Western blot result  is defined by the presence of any two of the 
following bands: p24, gp41 or gp120/160 for HIV-1 and gp34 or gp105 for HIV-
2. The assay is interpreted as negative by the absence of any reactivity [69,71,84].
As established by the interpretative criteria set by the CDC, a reactivity profile 
that does not meet criteria for either positive or negative results is considered 
indeterminate [85]. 
A reactive EIA testing, together with a positive Western Blot display a positive 
predictive value of greater than 99.99%.
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Line Immunoassay (LIA) is a confirmatory assay that incorporates separate 
recombinant HIV antigens on nitrocellulose strips so that each positive reaction 
result due to the presence of specific HIV antibodies can be visualized separately. 
The LIA offers the advantage of  eliminating the background from non-specific 
host cell proteins, as possible when using viral lysates, thereby decreasing the 
number of indeterminate results in non-infected persons.
Indirect Immunofluorescence Assay (IFA) allows for anti-HIV antibody 
detection, by using HIV infected cells (usually lymphocytes) fixed to a 
microscope slide. Serum is added and, if present, the anti-HIV antibodies react 
with the intracellular HIV before being detected with the fluorescent conjugate 
(anti-human immunoglobulin coupled with a fluorescent tag). This technique has 
the advantage of sometimes providing definitive results of samples that have 
yielded indeterminate results by Western blot analysis, but has the disadvantage of 
requiring an expensive and well-maintained fluorescence microscope and of a 
subjective interpretation. 
4.1.3 Direct detection of  HIV virus
During acute HIV infection, prior to the appearance of antibody, HIV infection 
can be diagnosed by the demonstration of circulating p24 antigen, or by the 
presence of viral RNA or DNA.
At present, the use of p24 antigen capture assay is very limited for diagnostic 
purposes, having been replaced with more sensitive nucleic acid assays [76]. 
Nucleic acid testing (NAT) is increasingly being used as a sensitive method to 
detect neonatal infections and also to identify acute antibody-negative/RNA 
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positive infections in high risk symptomatic adults [86,87]. The major NAT 
methods include the reverse transcription Polymerase Chain Reaction (rt-PCR), 
Nucleic Acid Sequence Based Amplification (NASBA) and signal amplification 
branched-chain DNA (bDNA).   
Although antibody tests constitute the mainstay of HIV diagnosis, antibody 
testing alone may fail to identify highly-infectious individuals during the first 
weeks after HIV infection. Viral nucleic acid detection can play a valuable role in 
identifying early infection within 9-11 days following exposure, before 
seroconversion occurs, thus allowing for early treatment and prevention of 
secondary transmission [88]. 
However, HIV nucleic acid testing hasn’t a 100% sensitivity and specificity: false 
positive results may occur in 2-5% of HIV NATs, especially when low RNA 
levels are detected, and false negative results may be reported in individuals with 
very recent HIV acquisition, depending on the existence of a narrow window 
period. In these cases, risk-reduction behaviour associated with repeated testing 
should be recommended [89, 90].
In addition to screening for HIV, molecular techniques provide quantification of 
viral nucleic acid in plasma (viral load), that is a strong predictor of the disease 
progression rate, thus establishing initial prognosis, determining the need for 
therapy and monitoring the effectiveness of anti-retroviral treatment [76]. These 
tests are very sensitive and the most used assays have a detection limit of 50 
copies/mL. 
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4.2 HIV testing in surveillance
Serosurveillance data are used to estimate HIV prevalence rates and geographical 
distribution of infection, as well as to monitor trends over time in specific 
population groups at increased risk for infection [91].
Linked testing confidential or anonymous is the preferred HIV testing approach, 
when the specimens are collected in population not accessible through clinic 
settings, such as injecting drug users, female sex workers and MSM. 
The state of epidemic (generalized, concentrated or low-level) determines which
population groups are surveyed: countries with low-level epidemics focus 
primarily on specific population groups who are perceived to be at high risk for 
infection and venues attended by target groups are selected as sentinel sites (drug 
treatment centres, bars, discos), whereas sentinel serosurveillance  among 
pregnant women at antenatal clinics are conducted in countries with generalized 
epidemics. 
Current UNAIDS/WHO recommendations on selection and evaluation of 
appropriate HIV testing technologies for surveillance purposes include a serial 
two-test strategy irrespective of HIV prevalence in the population being studied
[91-94] (Fig.3).
For those surveillance settings where test results are provided to survey 
participants, samples are initially tested with a high sensitive screening assay and 
reactive samples are retested with a second test. 
The first test should have as high a sensitivity as possible (at least 99%) and the 
second test should have as high a specificity as possible (at least 98%). 
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Fig. 3: Algorithm for HIV diagnoses in surveillance.
The first test is the screening test, so it is designed to detect all positives. A second 
test is used to confirm whether specimens found reactive with a particular 
screening test contain specific HIV antibodies. Because a few false positive
results may occur, the second test or confirmation test needs to be highly specific 
to ensure that all truly negative test results are identified as negative [94,95].
For surveillance, current testing procedure use latest generation enzyme immuno-
assay (EIA) tests, rapid tests based on different antigen preparations, or a 
combination of both. The preference of format will depend on several factors: EIA 
testing is usually preferred and cost-effective when larger numbers of specimens 
are to be run and when they can be batch processed; on the contrary, rapid tests 
may be preferred when small numbers of samples are being tested and a short 
turn-around time to provide results are available (“on site” testing). 
First Assay
First Assay  Reactive First Assay  non-Reactive
Second Assay NEGATIVE
RESULT
First Assay  Reactive
Second Assay Reactive
First Assay  Reactive
Second Assay non-Reactive
POSITIVE 
RESULT
Third Assay
Third Assay Reactive Third Assay Non-Reactive
POSITIVE
RESULT
NEGATIVE 
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A third different test (“tie-breaker”) should be carried out as a definitive 
confirmation assay in the event of discordance between the first and the second 
tests. Western blot can be suitable for this purpose. If Western Blot is negative, 
the result of the screening test is considered to be a false positive, indicating that 
the patient is not infected with HIV. If the confirmatory test is positive, a report is 
sent back with a confirmed positive statement. Indeterminate results may be found
up to 10% to 20% of cases and may be due to recently acquired HIV infections or 
to the interfering action of cross-reactive antibodies. Re-testing guidelines for 
indeterminate results recommend HIV testing to be repeated from 2 weeks to two 
months later for a definitive result.
Summing up, current guidelines recommend two different tests with a third test as 
a tie-breaker if the first two are discordant. Since a second sample for 
confirmation may not be feasible in surveillance settings being considered for 
hard-to-reach population, HIV determination is carried out by multiple tests on a 
single sample.
Samples are considered positive if they are reactive on two different tests. 
Samples that are not reactive with the first test are considered negative, as are 
those reactive on test one but non-reactive on both tests two and three.
4.3 Oral fluid testing
Although the serological identification of antibodies to HIV in blood is considered
the most extensively used method to detect HIV infection, in the context of 
epidemiological surveys, it is impractical to collect samples of venous blood for 
HIV testing [96,97]. Specimens should be obtained with minimal training and 
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minimal risk of infection and, sometimes under difficult field conditions. In 
addition, blood sampling may reduce participation and venous puncture may be 
difficult in certain groups, such as injecting drug users or subjects with a poor 
venous access [98].
Recently, however, the oral fluid testing been advocated as a non-invasive 
alternative to blood testing  for the detection of antibodies to a number of specific 
infectious diseases, including HIV infection [99-105].
For HIV prevalence surveys, where compliance with venipuncture may be low,  
the safety, the easy and non-invasive nature of collection, thereby obtaining large 
numbers of specimens within a short time period along with relatively low cost,
make oral fluid-based methods an attractive alternative strategy to venipuncture
and serological testing [106-109]. 
As a safe, non invasive and painless method, oral fluid testing collection offers a 
potential for a higher degree of acceptability among subjects being tested for 
surveillance purposes compared to drawing blood [100].
Therefore a greater percentage of the target population may agree to be tested, 
thus improving access to HIV screening and reducing the risk of selection bias
[92].
Young children represent an important group where oral  fluid samples are 
currently used as a non invasive alternative to serum for the surveillance of certain 
virus infections, particularly those that are vaccine preventable. In the UK, oral 
fluid sampling has been used for the surveillance of measles, mumps and rubella 
(MMR) since 1994 [110].
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However the main disadvantage when using oral fluids as testing samples is that 
the concentration of specific antibodies may not be sufficient to detect truly 
positive cases [92].
Oral fluid is a complex body fluid consisting of secretions from salivary glands 
and transudate from mucosal surfaces and the gingival crevice – so called gingival 
crevicular fluid– [100, 111,112]. Gingival crevicular fluid is a serum transudate 
that is derived from the continuous seepage of fluid from the gingival capillaries 
into the gingival crevice between the gum margin and the teeth. This fluid is rich 
in plasma-derived IgG, the predominant class of anti-HIV antibodies. Since the 
first prerequisite to an effective oral HIV test is to isolate a sample rich in IgG, 
hence an oral fluid sample that is well represented with crevicular fluid is most 
suitable for antibody testing [99,113]. The levels of IgG present in GCF vastly 
exceed those found in whole saliva (300:1) and are about 4 times less than those 
in serum (3,500 mg/L vs. 12,500 mg/L) [100,111-114]. Thus, GCF appears to be 
the main source of salivary IgG and the gingival crevice is an identifiable 
anatomic site that provide assayable source of IgG. 
However, the final IgG concentration found in oral fluid is about 1/800-1/1000 
that of serum, because of the dilution effect of pure saliva, necessitating extremely 
sensitive tests that are able to detect small quantities of antibody. This means that 
sensitive assays in combination with absorptive collectors designed to be placed 
in specific areas of the mouth are needed to detect anti-HIV antibodies in oral 
fluid [100,115]. Specialized devices have been developed to standardize the 
collection method of oral fluid specimens in detecting antibodies to HIV-1/2.
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They specifically collect oral fluid from areas of the mouth rich in crevicular 
fluid, by creating an osmotic gradient that enhances transudation of IgG across the 
mucosal surface [116].
Oral fluid collection devices involves placing either an absorptive pad along the 
tooth-gum margin for two minutes (i.e. OraSure; Orasure Technologies, 
Bethlehem, PA, USA) or a cotton roll under the tongue until an adequate amount 
of whole saliva is collected and an indicator of device turns blue (i.e. Omni-SAL; 
Saliva Diagnostic Systems, Vancouver, WA) or to suck a sponge (i.e. Salivette; 
Sarstedt Ldt., Leicester, UK) or a polystyrene sponge to be rubbed along the base 
of the gums, using an action similar to tooth-brushing (Oracol, Malvern 
Technologies, Worcester, UK) [110,117]. The first two devices include a 
preservative solution to maintain specimen stability.
The first studies carried out on whole saliva by using first-generation EIA testing 
or Radio-Immuno-Assay for HIV detection in seropositive patients yielded 
sensitivities of only 57-70% [99,118]. 
Modification of existing assays by increasing sample volume, decreasing the 
diluent volume or by lowering optical density cut-off to accommodate the use of 
saliva has resulted in sensitivities (97.9-100%) and specificities (100%) 
comparable to those observed in serum testing [119,120].
The first assays developed specifically for testing oral fluid were IgG capture 
radio-immunoassay (GACRIA) and IgG antibody capture ELISA (GACELISA), 
based on the principle of concentrating specific IgG from saliva by capturing them 
on a solid phase, so that even small amounts of HIV-specific IgG may be 
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revealed. Using optimal dilutions, GACELISA has shown sensitivities of 98-
100% and specificities around 100% [99,121-124].
Similarly, GACRIA exhibited sensitivities of 94.4-100% and specificities of 98.8-
100%, depending on the method used, when whole saliva was used [122,125].
The introduction of specifically designed oral fluid collection devices that 
concentrate and stabilize the salivary-associated immunoglobulins, together with 
appropriate testing assay resulted in sensitivity of 97.8-100% and specificities of 
99.2-100% [116,126-133].   
Rapid and simple “point-of-care” tests have also been used successfully to test 
oral fluids for HIV. Oral fluid-based rapid testing is a very important component 
of HIV control initiatives and programs [134].  
In particular, Oraquick Advance Rapid HIV-1/2 antibody test (OraSure 
Technologies), a qualitative, visually read lateral-flow immunoassay, was the first 
rapid HIV test approved by FDA for the detection of HIV-1/2 antibodies in oral 
fluid as a point of care (POC) test [135]. The test is reported as having 99.3% 
sensitivity and 99.8% specificity [136]. Post-marketing surveillance of the 
OraQuick Advance Rapid HIV-1/2 Antibody Test on whole blood and oral fluid 
yielded favourable results. Testing over 135,000 whole-blood samples and over 
26,000 oral fluid test yielded a specificity of 99,98% with a positive predictive 
value of 99,24% for blood, and specificity of 98,89% with a positive predictive 
value of 90% for oral fluids [137]. 
However, oral fluid rapid testing have some limitations: i. they cannot be used to 
perform additional testing for confirmation or for special studies; ii. they need 
37
trained medical staff at the point of care for interpretation of test results; iii. they 
have a higher cost per test than EIAs.
38
OBJECTIVE
In epidemiological surveillance, oral fluid testing appears more appealing than 
serological testing carried out on blood samples, due to its good feasibility in 
terms of ease of sampling collection, safety and acceptability to hard-to-reach-
population, as well as its potential for a performance in antibody assays 
comparable to those obtained with serum testing. In particular, EIA testing may be 
a cost-effective tool for HIV prevalence estimation in epidemiological studies, 
where large number of samples are processed at a time, with the additional
possibility for confirmation testing on the same sample.
This study was designed:
- To estimate the prevalence of HIV infection and associated socio-
demographic and behavioural factors  in a cohort of MSM enrolled in seven 
European countries by means of non-invasive oral fluid sample collection. 
Understanding the factors that may contribute to the early identification of 
HIV infections will allow for implementation of evidence-based preventive 
interventions.  
- To proceed to validation of a third-generation EIA test, CE marked for use 
with serum, (EIA GENSCREEN HIV 1/2 version 2;BIORAD) for detecting 
antibodies to HIV-1/2 on oral fluid samples. Performance evaluation was 
carried out by testing paired oral fluid and serum samples obtained from 
confirmed HIV positive patients and controls. This procedure was 
instrumental to ensure that the laboratory technique was able to reproduce, 
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when applied to oral fluid specimens, values on sensitivity and specificity, 
such as those obtained when serum was used. 
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MATERIAL AND METHODS
The study was undertaken in two phases: the validation study, followed by a 
multi-centre survey.
It involved the participation of health institutions from seven European countries:
- Czech Republic : National Institute of Public Health, Prague
- Greece : Hellenic Centre for Infectious Diseases, Athens
- Italy : Regional Centre for Health Promotion, ULSS 20 Verona; Department of 
Pathology, Section of Immunology and Microbiology, University of Verona; AIDS/STI 
Centre, ASL 2 Isontina, Gorizia 
- Romania : Public Health Institute, Timisoara
- Slovakia : National  Reference Centre for HIV/AIDS, University of Bratislava
- Slovenia : Regional Centre for Health Promotion, Maribor; Dermatovenerologic Clinic 
of University of Ljubljana
- Spain : AIDS/STI Epidemiological Centre, Catalonia, Barcelona
1. VALIDATION  STUDY
1.1  Study settings and participants
The study population included 498 subjects, of which 263 were HIV positive 
patients attending health facilities (hospital, labs) for treatment and/or follow-up 
and 235 were confirmed HIV negative individuals recruited among volunteers.
Participants were eligible if any of the following criteria were met: i.  adult age
(≥ 18 years old); ii. previously known HIV positive patients attending health 
facilities regardless of being in HAART therapeutic regimen or confirmed HIV 
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negative subjects, if recruited as negative controls; iii. willingness to sign an 
informed consent form to take part in the study; iv. accepting to provide both an 
oral fluid and blood sample. 
Demographic, behavioural and clinical data were collected by means of a 
structured and anonymous questionnaire administered by health and lab 
professionals in each participating country.
Patient anonymity was guaranteed, by labelling the samples and the information 
form with a computer-generated identifier barcode.   
1.2  Sample collection and testing
The oral fluid samples were collected by using the Oracol device (Malvern 
Medical Development, Worcester, UK), which consists of an absorbent foam 
swab fixed to a plastic stick and conserved in a capped tube. The swab is
specifically designed to concentrate the GCF from whole saliva, targeting the 
gums (Fig. 4). Patients were asked to rub the sponge firmly along the gum at the 
base of the teeth for approximately 1 minute, like a toothbrush. 
Fig. 4: Oracol collection device.
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The serum samples were obtained at the same time by venepuncture.
After collection, samples were kept frozen at -20°C until shipment to the Verona 
University Hospital Laboratory. A tag with computer-generated identifier barcode 
was attached to the biological sample tubes and to the information form.
1.2.1 Processing of oral fluid samples
On receipt to the laboratory, tubes containing the oral fluid swab were filled with 
0.5 ml of transport medium (phosphate-buffered saline, pH 7.2 with 10% foetal 
calf serum, 0.2% Tween 20, 0.5% gentamicin and 0.2% fungizone) and let stand 
at 4°C for 1 hour. Swabs were then removed from tubes, squeezing and twisting 
the sponge against the plastic wall to drain as much liquid as possible. Oral fluid 
was recovered by two turns of centrifugation at 2500 rpm for 10 minutes and at 
14000 rpm for 1 minute, collected in sterile test microtubes and then stored at 
-20°C, until testing.
1.2.2 Enzyme Immuno-assay (EIA) for detection of anti-HIV 1/2 IgG
All serum and oral fluid paired samples were tested for antibodies to HIV-1/2 by 
using EIA GENSCREEN HIV 1/2 version 2 (BIORAD). 
It is an enzyme immuno-assay based on a sandwich technology, intended to detect 
anti-HIV1 and/or anti-HIV2 antibodies in human serum or plasma. It is based on 
the use of a solid phase, coated with purified recombinant antigens (HIV1 gp160 
and gp25 proteins  and a peptide corresponding to an immuno-dominant epitope 
of HIV2 envelope glycoprotein) and a recombinant antigen-peroxydase compound 
(peptides corresponding to HIV1/2 immuno-dominant epitopes of the envelope 
glycoproteins and nucleocapsidic proteins). 
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Briefly, 75L of undiluted oral fluid and serum samples were added to 25 L of 
specimen diluent in microtiters, along with positive, negative and cut-off serum 
controls. The microtiter plate was then incubated in a microplate incubator at
37C for 30  5 minutes to allow for binding of anti-HIV 1/2 potentially present 
in the sample to the antigens fixed to the solid phase. The plate was then washed 
and incubated for 30 5 minutes with 100 L of peroxydase-conjugated purified 
HIV1 and HIV2 antigens at room temperature. After washing, 80 L of a 
substratum revealing the presence of the enzyme-conjugated antigens was added 
and incubated for 30 5 minutes at room temperature in the dark. The reaction 
was stopped by adding 100 L of a sulphuric acid solution. Finally, the resulting
absorbance values (OD) were read with a spectrophotometer at 620-700 nm of 
wave of length.
On oral fluid samples, no dilutions were made and oral fluids were added to wells 
corresponding to the total volume of serum samples. 
The manufacture’s controls were used to determine the cut-off for serum samples.
Cut-off values for oral fluid specimens were given by calculating the meanSD
absorption values (OD) of all oral fluid controls. 
A sample was identified as positive if the ratio sample optical density to cut-off 
was greater than 1.
1.2.3 Testing of oral fluid sample quality by determination of total IgG
To assure that the oral fluid sample found negative after testing was taken 
properly and in sufficient quantity, a total IgG quantification test was carried out. 
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The minimum IgG concentration that an oral fluid sample had to contain to be 
acceptable for the oral fluid assays was 3.5 mg/L [110,112,113].
The total IgG content of oral fluid samples was determined by using an enzyme 
immuno-assay (Human IgG ELISA Quantification kit; Bethyl Lab. inc). 
The assay procedure involved the following steps:
- Microplate loading with 100 µL of oral fluid samples diluted 1:250 and 
standard dilutions of human IgG to be assayed in duplicate;
- Coating microtiter well strips with capture anti-human IgG antibody (purified 
goat anti-human IgG antibody);
- Microplate incubation at room temperature for 1 hours and washing out of 
unbound sample material;
- Addition of horseradish peroxydase (HRP) labelled anti-human IgG 
conjugate;
- Microplate incubation at room temperature and washing out with wash 
solution;
- Incubation with a tetramethylbenzidine (TMB) substrate revealing the 
presence of the bound conjugate by a blue reaction product.
- Addition of sulphuric acid to stop the reaction;
- Detection of the reaction by reading the absorbance values with a microtiter 
plate reader at 450 nm of wave of length. Individual specimen IgG 
concentration were extrapolated from the averages of absorbance readings of 
each set of oral fluid samples tests on a standard curve, created by using 
Softmax Pro 4.325 (Life Sciences Edition).
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1.3  Statistical analysis
The main outcomes were diagnostic accuracy measures of EIA testing on oral 
fluids, estimated by using sensitivity, specificity and predictive values, along with 
95% confidence intervals (CI). The detection of anti-HIV antibodies in serum 
samples with Genscreen was used as gold standard.
Concordance between results obtained with oral fluid and matched serum samples 
was established by using the kappa statistics. The following interpretation of the 
kappa value was used: k<20% poor, k=20-40% fair, k=41-60% moderate, k=61-
80% good, k=81-100% excellent agreement. The diagnostic testing accuracy was 
obtained by determining the ROC area.
Cut-off values were calculated as the mean of the OD controls +3 and +5 standard 
deviations (SD). A t-test was performed for comparison of oral fluid and serum 
mean OD/CO ratios. Analysis was carried out by using Microsoft Excel 2003.
2. MULTI-CENTRE SURVEY
2.1  Study settings and participants
A multi-centre cross-sectional survey for HIV prevalence determination by using 
oral fluid was undertaken among 2688 MSM between April 2008 and September 
2009. Recruitment and sample collection occurred  in preliminarily mapped 
venues (bars, discos, clubs) in each country.
Participation was voluntary and anonymous. Respondents were eligible if any of 
the following criteria were met:  i. adult age (≥ 18 years old); ii. accepting to 
provide an oral fluid sample and to fill in a questionnaire.
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They were informed of the aims of the study and were given a card with 
information on the closest HIV screening and counselling centre, where people 
can get the test result and receive post-test counselling. Since the test result based 
on oral fluid sample is not meant to be diagnostic, volunteers were informed that 
they should be tested again with another test performed on serum or oral fluid 
according to their wish. A structured questionnaire to obtain information 
concerning demographic and behavioural data was administered by trained 
personnel.
Barcode tags were stuck on biological samples and on the corresponding 
questionnaire to enable reliable tracking without using personal data to identify 
subjects. 
2.2  Sample collection and testing
Oral fluid specimens were obtained with the Oracol device (Malvern Medical 
Development, Worcester, UK) and tested for antibodies to HIV-1/2. 
Sample storage and processing was performed as described above in the 
validation study.
2.2.1 Enzyme Immuno-assay (EIA) for detection of anti-HIV 1/2 IgG
Oral fluid samples were tested for anti-HIV 1/2 antibodies by using EIA
GENSCREEN HIV 1/2 version 2 (BIORAD).
2.2.2 Total IgG quantification
To ensure that the oral fluid sample found negative after testing was taken 
properly, a total IgG quantification test was carried out. An oral fluid sample had 
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to contain at least 3.5 mg/L IgG to be acceptable for the oral fluid assays, 
otherwise it was excluded from data analysis.
2.3  Statistical analysis
HIV prevalence was defined as the number of confirmed HIV seropositive 
subjects divided by the total number of HIV-tested individuals during the study 
period. We also calculated 95% interval confidences (95% IC).
A chi-square test was carried out for comparison of prevalence rates.
Socio-demographic (age, educational attainment, environmental context) and 
sexual behavioural data (self-reported serostatus, STI history) were evaluated in 
association with HIV-1/2 positivity. 
Statistical analysis was performed by using Microsoft Excel 2003 package.
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RESULTS
1. ALGORITHM FOR VALIDATION OF HIV ORAL FLUID TESTING
Oral fluid samples, that tested positive by EIA Genscreen were compared to 
serum EIA results. If serum specimen was reactive for HIV-1/2 antibodies, a 
positive concordant result was reported (Fig.5). On the contrary, if serum 
specimen displayed non-reactivity to EIA testing and belong to the control group, 
the oral fluid testing result was reported as false-positive for HIV.
In the event of oral fluid sample non reactivity to EIA testing, IgG content was 
determined to assure that the negative result was reliable. Only valid samples 
were compared to serum results. If serum assay was concordant with oral fluid 
testing, a negative result was reported. On the other hand, if serum testing was 
reactive, the oral fluid assay was considered a false negative result.
Fig. 5: Validation of HIV oral fluid testing.
Oral Fluid EIA Testing
Positive Negative
Total IgG quantityIf Positive serum If Negative serum
POSITIVE  
RESULT
FALSE POSITIVE
RESULT
IgG <3.5 mg/L IgG ≥3.5mg/L
Invalid sample Valid sample
If Negative serum If Positive serum
NEGATIVE  
RESULT
FALSE NEGATIVE  
RESULT
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2. SURVEY HIV TESTING STRATEGY
Oral fluid samples yielding a positive result to EIA were tested for confirmation 
by using an immunochromatographic assay (Determine HIV-1/2; Inverness 
Medical, Abbott Laboratories; Abbott Park, IL) (Fig. 6). 
The immunochromatographic assay is a visually read, qualitative assay that is 
based on the use of recombinant antigens and synthetic peptides specific for HIV-
1/2  envelope proteins. If antibodies to HIV-1/2 are present in oral fluid sample, 
they bind to an antigen-selenium colloid conjugate and to HIV-specific antigens at 
the test location, causing a red line to appear. 
Fig. 6: Algorithm for oral fluid testing in surveillance.
If both EIA and rapid test were reactive, the result was reported as positive for 
HIV infection. If the rapid test was non-reactive, oral fluid specimens were 
subjected to Western blot analysis (HIV Blot 2.2; MP Biomedicals Asia Pacific 
Pte Ltd., Singapore) for definitive characterization. The WB combined purified 
Oral Fluid EIA Testing
Positive Negative
Rapid Test Total IgG quantity
Positive Negative IgG <3.5mg/L IgG ≥ 3.5mg/L
Invalid sample Valid samplePOSITIVE
RESULT
Western Blot
NEGATIVE 
RESULT
Positive Indeterminate Negative
POSITIVE
RESULT
INDETERMINATE
RESULT
FALSE POSITIVE
RESULT
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HIV-1 antigens (corresponding to the structural products of gag, pol, env genes) 
with an HIV-2 synthetic peptide in one strip. CDC criteria for determining 
western blot results were used to assign the final status of such samples [83].
On the other hand, oral fluid samples showing no reactivity to EIA testing were 
checked for total IgG concentration. If IgG content was sufficient, a negative 
result for HIV-1/2 antibodies was reported.
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3. VALIDATION STUDY
3.1 Soundness of commercial kits used in the validation and survey analytical        
sessions
3.1.1 Inter-assay reproducibility of Genscreen HIV 1/2 version 2 (BIO-RAD)
No significant OD variability in positive (mean: 3.06±0.27) and negative (mean: 
0.16±0.03) control sera was observed  among different analytical sessions.  
The inter-test variability of positive and negative control sera provided by the kit 
manufacturer is shown in Figure 7.
Fig. 7: Distribution of EIA Genscreen HIV-1/2 control sera.
3.1.2 Inter-assay reproducibility of Human IgG quantification kit
The standard curve points corresponding to human IgG standard dilutions (500-
7.8 ng/ml) were generated with good reproducibility among independent runs.
The inter-test variability of reference curve provided by the kit manufacturer is 
described in Figure 8.
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Fig. 8: Standard curve of Human IgG quantification EIA.
3.3 Performance of oral fluid EIA testing
The sample set included 263 paired serum and oral fluid samples from confirmed
HIV positive patients and 235 samples from HIV negative subjects.
The contribution from each European country is shown in Table IV.
Table IV : Study population recruited by country.
Country HIV-positive patients HIV-negative subjects
CZECH REPUBLIC 37 30
GREECE 40 33
ITALY 38 32
ROMANIA 37 35
SLOVAKIA 37 35
SLOVENIA 37 35
SPAIN 37 35
TOTAL (N=498) 263 235
The socio-demographic profiles of individuals recruited in the study are shown in 
Table V and VI.
ng/ml OD values
500 2.47±0.007
250 2.2±0.09
125 1.8±0.08
62.5 1.1±0.06
31.25 0.61±0.04
15.625 0.27±0.02
7.8 0.14±0.04
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Table V: Demographic and clinical features of the HIV positive patients (N=263).
Age (mean ±s.d.; range) 39.9±10.9 ys (20-75 ys)
Gender 56 females, 205 males
HIV risk factors
Heterosexual : 68/263 (26%)
MSM : 139/263 (53%)
IDU : 19/263 (7%)
Unknown : 37/263 (14%)
Median time from HIV seroconversion (years) 7,8 ys
Antiretroviral treatment (HAART) (%) 164/263  (62.4%)
Previous STI (%) 62/263   (23.6%)
Table VI: Demographic data of the HIV negative subjects (N=235).
Age (mean ±s.d.; range) 33.6±11.2 ys (19-86 ys)
Gender 83 females, 150 males
The mean age of the HIV-positive patients was 39.910.9 years (range:20-75 ys); 
78.5% was male. More than half patients identified themselves as MSM; a 
heterosexual mode of transmission was described in a quarter of cases of HIV 
infection, while IDU accounted for 7% of all recruited patients. Data about HIV
probable route of transmission were unknown in 14% cases. More than a fifth of 
patients reported a history of previous sexually transmitted infections (STIs). 
Antiretroviral therapeutic regimen had been administered to more than 60% of 
patients enrolled.
Among the control subjects, the mean age was 33.611.2 years and 64.4% were 
male.
HIV antibodies were determined by using EIA Genscreen HIV 1/2 and the oral 
fluid samples were tested in the same way as the sera, following the
manufacturer’s package instructions.  
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Among  the HIV seropositive patients, antibodies to HIV were detected in 259
out of 263 (98.5%) oral fluid samples and in all 263 (100%) matched sera by 
Genscreen (Fig.9,10).
n=263 n=259
n=233 n=233
n=4
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Fig. 9: Oral fluid testing results vs. serum by using EIA Genscreen.
HIV negative subjects        HIV positive subjects
Fig. 10: Performance of EIA Genscreen HIV-1/2 on oral fluid samples vs. serum.
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Among the HIV-seronegative group, of the 235 tested paired samples, the totality 
was Genscreen test negative. All oral fluid samples were subjected to an IgG 
quantification assay and 233 out of 235 (99.1%) provided a valid result (mean IgG 
concentration of 24.41 mg/L). 
EIA GENSCREEN HIV 1/2 version 2 (BIORAD) performed on oral fluid 
specimens exhibited a sensitivity of 98.5% (95% CI: 96.2-99.6) and a specificity 
of 100% (95% CI: 98.4-100). 
Thus, given a prevalence of more than 50% (as in this study), the positive 
predictive value (PPV) was 100% (95% CI: 96.8-100) and the negative predictive 
value (NPV) was 98.3% (95% CI: 95.7-99.5). 
The positive and negative predictive values were calculated for different 
prevalences of HIV (Table VII). Taking into account a specificity of 100%, the 
positive predictive value was 100% regardless the HIV prevalence in the 
population. The negative predictive value ranged from 99.9% for a population 
with a HIV prevalence of 0.5% to 98.8% for a population with a HIV prevalence 
of 80%.
Table VII: PPV and NPV of HIV EIA oral fluid testing for different prevalences.
Prevalence 0.5 1 5 10 15 50 80
PPV (%) 100% 100% 100% 100% 100% 100% 100%
NPV (%) 99.9% 99.9% 99.9% 99.8% 99.8% 99.3% 98.8%
The concordance between results obtained in serum and oral fluid specimens was 
excellent according to the Kappa index (k=0.98; 95% CI: 0.968-1); the diagnostic 
accuracy as expressed by the ROC area was 0.992 (Table VIII).
56
Table VIII: Performance of EIA oral fluid testing.
Test Sensitivity  Specificity  Kappa statistics ROC area
Genscreen HIV 1/2 98,50% 100% 0.98 0.992
However, 4 discrepant results were obtained among serum and oral fluid samples 
from previously known HIV-seropositive patients. In all these cases, HIV 
antibodies were detected in serum but not in oral fluid samples by EIA, even after 
repeat testing. IgG quantification assay indicate that these samples were taken 
properly (IgG values were far above the limit value of 3.5 mg/L; mean IgG: 36.5 
mg/L). Additionally, both sera and oral fluid specimens were verified with WB to 
confirm the presence of HIV antibodies. When tested by using WB, all serum 
samples remained positive for HIV, whereas 3 out 4 oral fluid samples fulfilled 
the positivity criteria for WB and 1 displayed an indeterminate result (Table IX, 
Fig. 11).
The 4 patients incorrectly identified as HIV negative by using oral fluid testing 
were recorded as receiving antiretroviral treatment, with CD4+ counts ranging 
from 452 to 1039 cells/µL and a viral load less than 50 copies/mL. 
Table IX: Results of HIV confirmation testing from previously known HIV 
positive subjects with negative oral fluid (OF) samples. 
Subject
No.
IgG
(mg/L)
HIV EIA
serum
HIV EIA
OF
WB
serum
WB
OF
1 29.4 Pos Neg Pos Ind
2 14 Pos Neg Pos Pos
3 51.1 Pos Neg Pos Pos
4 51.5 Pos Neg Pos Pos
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Fig. 11: Reactivity observed by WB of EIA discordant serum and oral fluid 
samples.
Oral fluid testing yielded  a false negativity rate of 0.8%, while no false positivity 
rate was observed.
The mean optical densities (OD) of the 233 oral fluid controls was 0.05 and the 
SD was 0.03.Thus, the cut-offs for the assay using +3SD and +5SD were 0.14 and 
0.20, respectively. The assay displayed the best sensitivity  and specificity when a 
cut-off of 5 SD above the mean value for controls was used.
The distribution of optical densities in the EIA oral fluid testing from HIV-
negative subjects coincided closely with that of sera from the same individuals
(Fig. 12). 
Our findings indicated that the cut-off value based on the control sera included in 
the kit was also suitable for OF testing.
58
Fig. 12: Calculated cut-off value for oral fluid testing vs. serum.
The mean optical density to cut-off ratios (OD/CO) in serum and oral fluid 
samples among subjects testing concordantly positive, concordantly negative and 
falsely negative in oral fluid assay are shown in Table X. 
Table X: Mean OD/CO ratio by EIA testing result.
OD/CO
Concordance 
negative 
N=233
Concordance 
positive      
N=259
Discordant
N=4
Serum 0.35 24.06 14.77
Oral Fluid 0.36 20.41 0.62
The serum OD/CO of samples tested false negative by the oral fluid assay and
those tested concordantly positive differed with statistical significance (14.77 vs 
24.06; p<0.001). Similarly, the oral fluid OD/CO ratios of the false negatives were 
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significantly higher than those of the concordantly negative (0.62 vs 0.36; 
p<0.003). 
In the attempt to improve the sensitivity of oral fluid-based assays, the minimum 
and maximum OD/CO values in the EIAs of the concordantly positive and 
concordantly negative oral fluid samples were compared to determine a lower 
OD/CO ratio. The maximum  OD/CO ratio for concordantly negative oral fluid 
samples was 1; among concordantly positive oral fluid samples, the minimum 
OD/CO in the EIA was 1.05. Therefore, no adjustment could be done on the cut-
off while testing oral fluids, without compromising the assay specificity.
These data are consistent with a high degree of concordance of Genscreen HIV-
1/2 EIA testing results between serum and oral fluid specimens. No modifications 
of package instructions that optimized the kit for use with saliva were applied.  
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4. MULTI-CENTER SURVEY
4.1 Study population
A total of 2688 MSM were tested by EIA Genscreen for HIV-1/2 antibody 
determination on oral fluid samples and provided questionnaires (Table XI).
Table XI : Study population recruited by country.
Country MSM enrolled in the survey
CZECH REPUBLIC 418
GREECE 178
ITALY 500
ROMANIA 398
SLOVAKIA 396
SLOVENIA 399
SPAIN 399
TOTAL 2688
The mean age of the people under investigation was 32± 9.8 years (range:18-
76 ys). Respondents in Southern European countries were older than those in the 
Eastern countries (36±10 ys vs. 29±8 ys; p<0.05) (Fig. 13).
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Fig.13: Age distribution of MSM enrolled in the multi-center survey by country.
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More than two-thirds of participants (70%) reported living in urban settings, while 
the remainder were from small towns or villages. The proportion of MSM with a 
secondary qualification was 52%, whereas 40% had a university degree; the 
highest proportion of university qualifications was found in Greece (57%), while 
the lowest was in Czech Republic (27%).
More than 80% self identified themselves as homosexual; bisexuals accounted for 
18% and heterosexuals were 2%. MSM in Italy had the highest proportion of 
respondents who reported being homosexual (more than 90%) and MSM in 
Greece had the lowest (65%) (Fig. 14).
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Fig. 14: Overview of respondents’ sexual behaviour by country.
A history of previous STIs was documented in 4% cases for syphilis, in 5% for 
gonorrhoea and 4% for infections by Chlamydia.
More than a half of MSM reported HIV testing in the last 12 months; the higher 
proportion was found in Greece (94%) and the lowest in Slovakia (38%) (Fig.15).
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Fig.15: Proportion of subjects undergoing HIV testing in the previous 12 months.
4.2   HIV prevalence
EIA testing resulted in 208 (7.7%) reactive oral fluid samples and 2480 (92.3%) 
negative results (Fig. 16) (Table XII).
Fig. 16: EIA Genscreen HIV-1/2 microplate (blue: reactive; pink: non-reactive).
Table XII: EIA testing results on oral fluid samples.
Country Positive EIA Negative EIA
Czech Republic         (n=418) 11  407
Greece                       (n=178) 15  163
Italy (n=500) 52  448
Romania (n=398) 17 381
Slovakia (n=396) 23  373 
Slovenia (n=399) 24  375
Spain (n=399) 66  333
Total (n=2688) 208 2480
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Of the 208 EIA reactive samples, 151 out of 208 (72.6%) were confirmed positive 
by a second test (rapid test). Remainder were tested for confirmation by using 
Western Blot (WB): 45 out of 57 oral fluid samples fulfilled the positivity criteria 
for WB, 2 samples displayed an indeterminate result and 10 gave a negative result 
(Table XIII).
Table XIII: Confirmation assays for EIA positive oral fluid specimens.
Western Blot
Country ReactiveEIA test
Reactive
rapid test Positive Indeterminate Negative
Total No 
confirmed 
positive result
Czech Rep. 11 10 0 0 1 10
Greece 15 12 3 0 0 15
Italy 52 34 14 0 4 48
Romania 17 9 6 1 1 15
Slovakia 23 15 7 1 0 22
Slovenia 24 18 2 0 4 20
Spain 66 53 13 0 0 66
Total 208 151 45 2 10 196
Of the samples tested negative by EIA, 153 out of 2480 (6.2%) were considered 
not valid and thus excluded from data analysis, because an insufficient IgG 
content. This resulted in a number of oral fluid (OF) samples considered 
appropriate for HIV testing of  2535 (Table XIV).
Table XIV: Oral fluid samples appropriate for HIV testing by IgG determination.
Country No. oral fluid tested samples
No. oral fluid
invalid samples
No. oral fluid
valid samples
Czech Republic         418 31 387
Greece                       178 28 150
Italy                           500 11 489
Romania                   398 53 345
Slovakia                    396 10 386
Slovenia                    399 10 389
Spain                        399 10 389
Total                        2688 153 2535
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The results obtained in the survey by HIV oral fluid testing are summarized in 
Table XV.
Table XV: Overview of survey results on oral fluid samples.
The overall prevalence rate of HIV infection among tested MSM was 7.7% (196
out of 2535 men, 95% CI: 6.7-8.7%) (Table XVI).
Table XVI: Prevalence of HIV infection among MSM in South-Eastern Europe.
Country Confirmed HIV positive OF samples HIV prevalence (95% CI)
Czech Republic 10/387     2.6% (1-4.2%)
Greece 15/150     10% (5.2-14.8%)
Italy 48/489     9.8% (7.2-12.4%)
Romania 15/345     4.3% (2.2-6.4%)
Slovakia 22/386     5.7% (3.4-8%)
Slovenia 20/389     5.1% (2.9-7.3%)
Spain 66/389     17% (13.3-20.7%)
Total 196/2535   7.7% (6.7-8.7%)
A significant difference in HIV prevalence among MSM between Southern and 
Eastern European countries was observed 12.3% [10.3-14.3%] vs. 4.4% [3.4-
5.4%]; p<0.001) (Fig. 17).
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Fig. 17: HIV prevalence rates among MSM by country.
Spain had the highest proportion of HIV affected subjects (17%) followed  by
Greece (10%) and Italy (9.8%). On the other hand, the lowest HIV prevalence 
rates were found among MSM in Czech Republic (2.6%) and Romania (4.3%).
The age-specific HIV prevalence was analyzed and is shown in Fig. 18.
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Fig.18: HIV prevalence by age.
People aged more than 25 years displayed a significantly higher HIV prevalence 
than other age-groups (3.5% vs 9.6%; p<0.001).
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About a half of MSM with positive results on oral fluid testing were unaware of 
their real HIV status; the highest proportion was found in Slovenia (68%) and the 
lowest in Spain (38%) (Fig. 19).
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Fig.19: Proportion of HIV positive subjects unaware of their own serostatus.
Among the subjects tested HIV positive on oral fluid samples, those reporting the 
last negative HIV test within the previous 12 months were 52% (Fig. 20).
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Fig. 20: Degree of HIV serostatus awareness among MSM tested HIV positive.
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In addition, 16% of people who had an STI in the last 12 months were also HIV 
positive compared to 6.6% of people who didn’t (p<0.001).
These data confirm that MSM represent a population at high risk for HIV 
transmission, where the awareness of real HIV serostatus lacks in nearly half 
cases of infected people.
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DISCUSSION
1. VALIDATION STUDY
Since it has been reported that antibodies to HIV would be reliably detected in 
oral fluid samples of HIV infected patients, the present study evaluated the 
feasibility of an EIA oral fluid testing for anti-HIV antibodies in comparison to 
serum [99,112,116,119,138-142].
On validation phase, we obtained a striking concordance when paired serum and 
oral fluid samples were tested for anti-HIV antibodies by using Genscreen HIV 
1/2 version 2 (k=0.98). The sensitivity and specificity of this assay on oral fluid 
samples was 98.5% and 100%, respectively.
These results suggested that  Genscreen HIV 1/2 version 2 was a suitable assay 
for detection of antibodies to HIV-1/2 in oral fluids, thus finding an application in 
epidemiological surveys on HIV occurrence in high risk population.
There were 4 out of 263 specimens from HIV-seropositive subjects that were 
found discordant with regard to their EIA reactivity when serum and oral fluid 
were assayed; among them, 3 oral fluid samples were positive by WB, whereas 1 
gave an indeterminate result.
Considering the number of false negative oral fluid results by country, 2 samples 
were from Slovenia (Se=97.2%), 1 from Greece (Se=98.6%) and 1 from Spain 
(Se=98.6%), whereas Czech Republic, Italy, Romania and Slovakia showed no 
discordant specimen results (Se=100%).   
Reasons for these 4 false-negative results are difficult to pinpoint.
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Although testing these samples for total IgG revealed a sufficient content in all 
four cases, it has to be considered that the quantification of IgG does not prove 
their intact function.
It is therefore conceivable that low specific or bacterial degraded IgG anti-HIV 
antibodies may have not reached the minimal threshold required to give positive 
OD in EIA [100,143]. Consistently with this hypothesis, the 5-fold amount of oral 
fluid used in Western blotting showed positive results in 3 over 4 samples.
A concomitant factor, previously observed in association with false negative 
reports on oral fluid testing, was the early initiation of antiretroviral treatment, due 
to its potential for decreasing specific serum antibody levels [144]. In this study, 
all these 4 patients were under antiretroviral therapeutic regimen. 
The occurrence of  false negative results may also be linked to the intrinsic limit 
of detection of the EIA assay, which is supported by the lower OD/CO ratio
exhibited by concordantly negative oral fluid samples as compared to that found
in false negative samples. However, by lowering the cut-off, the sensitivity of EIA 
testing on oral fluid specimens would improve, despite of specificity. Thus for 
epidemiological purposes an OD/CO ratio greater than 1 could be acceptable, to 
avoid the appearance of false positives. 
We chose this oral fluid collection device, because it is cheap, safe and acceptable 
to individuals of all ages, and proved to yield high quality oral fluid samples for 
antibody testing in terms of total and specific antibody concentrations [110,117].
This device is designed to target the gum, the part of the oral cavity most likely to 
be rich in gingival crevicular fluid. 
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As opposed to blood, the collection of oral fluid is non-invasive, safe (as viral 
load is undetectable in oral fluid) and more cost effective. The combination of an 
adequate oral fluid collection device and a highly sensitive antibody detection 
assay may offer a good alternative to techniques based on serum for the 
surveillance of viral infections among high risk population. In this study, the oral 
fluid collection device used for detection for HIV antibodies was well-accepted, 
thus promoting high compliance among participants and proving to be ideally 
suited for field collection. 
2. MULTI-CENTER  SURVEY
With an estimated 40% increase in the proportion of HIV new infections due to 
MSM in Europe between 2003 and 2008, there is a need for surveillance
interventions as efficient tools to monitor the HIV epidemic among this high-risk 
group [14,145].
We conducted a multi-center survey with the aim to establish the prevalence of 
HIV infection in MSM from seven Southern and Eastern European countries by 
using the previously validated EIA Genscreen HIV-1/2 version 2 (BIO-RAD) on 
oral fluid samples.
We found complete concordance between the reactive results from EIA oral fluid 
testing and confirmatory testing (rapid test or Western Blot) in 196 out of 208 
cases (94.2%), whereas the rate of false positive results was 5.8%.
In our study, overall prevalence of anti-HIV antibodies among MSM was found to 
be 7.7% (196 out of 2535 men, 95% CI: 6.7-8.7%), a value much higher than that 
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estimated in European adult population (0.3%), suggesting that MSM are yet to 
have a major impact on the HIV epidemic [26]. 
In Spain, HIV prevalence rate among MSM was 17%, in concordance with 
prevalence data reported in a previous cross-sectional study conducted in 
Catalonia (18%) [15,16,26,146].
In Greece, where more than 50% of new HIV infections have been reported to be 
among MSM, the HIV prevalence rate has been high (10%) [15,147,148].
In Italy, the HIV prevalence observed in sentinel sites like Verona and Gorizia 
was 9.8%. This data associated with previous reports about relevant increase in 
HIV incidence observed among MSM in Rome from 1995 to 2003 (2.2% to 5%) 
show the spread of HIV infection among MSM to be continuing [149].
Similar to other studies carried out in Slovakia, a HIV prevalence of 5.7% among 
MSM was described [150,151]. In this country, MSM account for half newly 
diagnosed HIV infections [150].
The burden of HIV among MSM in Slovenia is disproportionally high (more than 
70% cases of new infections) and exhibits an increasing trend (from 2.5 to 16.7 
per million between 1999 to 2008) [150,152]. We estimated an HIV prevalence 
rate of 5.1%, that is higher than that reported from previous studies (2.1-3%) 
[16,29,152].
Romania and Czech Republic had HIV prevalence rates of 4.3 and 2.6%, 
respectively. A minimal proportion of all new HIV infections (5%) are due to 
MSM in Romania, where the leading route of transmission of infection is through 
heterosexual contact [16,150].  In Czech Republic, MSM account for 57% of all 
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reported HIV cases and HIV prevalence rates among MSM in previous reports 
ranged from 0.5% to 1.4% [16,28,150,153]. 
The association between age and anti-HIV prevalence was statistically significant  
in those 25 years or older as compared to younger subjects.
A history of STIs in the last 12 months was significantly associated to anti-HIV 
positivity (p<0.001). This is concordant with previous reports that genital ulcer 
diseases such as syphilis may increase the risk of HIV transmission, enhancing 
both the infectiousness of HIV and susceptibility to the virus [154,155].
With respect to access to HIV testing in the last 12 months, the highest percentage 
of tested MSM was found in Southern European countries as compared to Eastern 
countries, thus indicating a better voluntary counselling testing practice (65.8% 
vs. 44.9%; p<0.001).
About a half of MSM with positive results on oral fluid testing were unaware of 
their real HIV status; in particular, it raises concerns that the highest proportion of 
unaware HIV positive subjects were from Slovenia (68%), where HIV prevalence
among MSM, the main driver of the epidemic in the country, has increased by 8 
times in the last decade.
Despite of a negative HIV test report within the previous 12 months, more than 
half HIV positive subjects weren’t aware of their real serostatus. This data suggest 
that these subjects had been infected during the last year and so relying only on a 
past negative test result may be an ineffective prevention strategy without
additional behavioural interventions. 
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It is important to highlight that the overall HIV prevalence rate among MSM from 
Southern European countries was found to be significantly higher than that of  
Eastern countries, thus resembling higher rates of infection in adult population in
Southern countries (0.3%) as compared to Eastern European region (0.1%) [16].
These data indicate that MSM have a one in eight odds of becoming infected with 
HIV infection in Southern Europe and a one in twenty-three odds in Eastern
countries. Therefore, interventions focusing on reducing risk behaviour and 
preventing secondary transmission of HIV infection are urgently needed among 
this high risk group.
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CONCLUSION
Our findings demonstrate for the first time that EIA Genscreen HIV-1/2 version 2 
is a valuable tool for epidemiological surveillance of HIV infection, due to its 
reliability, convenience and user-friendliness. 
In non-clinical settings, oral fluid-based linked HIV testing strategies would 
provide hard-to-reach population with access to testing services, thus increasing
the awareness about their HIV serostatus. In addition, this allows for an estimation 
of prevalence rates of infection for surveillance purposes. 
We conducted a large survey, where oral fluid-based testing was successfully used 
to obtain a one-time estimation of HIV prevalence from a large cohort of MSM at 
risk for infection in seven EU countries. The results of this multi-center study
emphasize the high prevalence rate of HIV infected people among MSM, 
especially in Southern Europe and consequently the need for interventions aimed 
at encouraging behavioural changes among this high risk group.
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